Vaxcyte (PCVX) AI Stock Analysis

• Market Cap: $4.24B
• Dividend Yield: N/A
• Average Volume (3M): 1.84M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: N/A
• EPS Growth: 7.75%
• Country: US
• Employees: 414
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.04
• Shares Outstanding: 129,004,140
• 10 Day Avg. Volume: 1,384,055
• 30 Day Avg. Volume: 1,835,237
• PEG Ratio: -0.14
• Price to Book (P/B): 3.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.63
• Enterprise Value/Market Cap: 0.54
• Enterprise Value/Revenue: 79.41
• Enterprise Value/Gross Profit: -287.46
• Enterprise Value/Ebitda: -1.09
• 1Y Price Target: $117.88
• Price Target Upside: 258.62% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

• Rating: 50 Neutral
• Price Target: ―

Vaxcyte's stock score reflects its position as a development-stage biotech firm with no revenue, high R&D expenses, and reliance on financing. The technical analysis indicates a bearish trend, while valuation metrics show challenges due to negative earnings. However, the company's robust pipeline and recent positive clinical results provide optimism for the future. The earnings call and corporate events signal potential for growth, but regulatory and financial challenges remain.

Positive Factors

Financial Stability

The company reported approximately $3.0B in cash, cash equivalents, and investments.

Market Potential

If Pfizer or other companies cannot pursue a 30+ valent vaccine, then VAX-31 will become the new Prevnar because it will have a meaningfully differentiated serotype coverage profile.

Pipeline Progress

PCVX plans to initiate the Ph3 pivotal study of VAX-31 in adults and disclose topline safety/immunogenicity data.

Negative Factors

Clinical Data Concerns

The VAX-24 infant study missed post-dose 3 primary serotype conversion rate non-inferiority criteria on 4 of 24 serotypes relative to Prevnar 20.

Price Target Reduction

Following PCVX’s disappointing Ph2 VAX-24 infant data, the price target is reduced from $153 to $65.

Regulatory Challenges

Anti-vaccine news flow and regulatory uncertainty out of HHS/FDA, including this week's appointment of Dr. Vinay Prasad as head of CBER, continue to put pressure on shares.

Vaxcyte Business Overview & Revenue Model

Company Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

How the Company Makes Money

Vaxcyte makes money primarily through the development and commercialization of its vaccine candidates. The company's revenue model involves research and development (R&D) investments to advance its vaccine pipeline through clinical trials, regulatory approval, and ultimately, market launch. Key revenue streams include potential product sales, milestone payments, and royalties from partnerships or licensing agreements with other pharmaceutical companies. Additionally, Vaxcyte may benefit from government grants or funding to support vaccine development. Strategic collaborations with industry partners can also contribute to its earnings by sharing development costs and expanding market reach upon commercialization.

Vaxcyte Financial Statement Overview

Summary

Vaxcyte is in a typical financial position for a biotech firm at its stage: no revenue, significant R&D investment, and reliance on financing to maintain liquidity. The strong equity base and cash reserves provide a buffer against short-term challenges, but the company needs to transition to revenue generation to improve its financial health in the long term.

Income Statement

Vaxcyte has consistently reported no revenue, which is typical for early-stage biotechnology companies focusing on product development. The company has a negative EBIT and EBITDA, indicating ongoing operational losses. The net income has been negative over the years, reflecting substantial R&D and operating expenses without offsetting revenue. However, this is a standard profile for a biotech firm in the development phase.

Balance Sheet

The company's balance sheet shows strong liquidity, with cash and short-term investments significantly exceeding total debt, resulting in a negative net debt. The stockholders' equity is robust, and the equity ratio is high, indicating financial stability. However, the lack of revenue generation and increasing liabilities over time are potential concerns if the trend continues without revenue.

Cash Flow

Operating cash flow is negative, reflecting the company's pre-revenue stage and heavy investment in R&D. Free cash flow is also negative, though financing activities have been strong, suggesting continued investor confidence. The company has maintained its cash position through financing, offsetting the negative cash flow from operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-7.98M	0.00	-75.00M	-9.20M	-1.80M	-1.41M
	EBIT
-635.87M	-569.55M	-468.04M	-232.26M	-103.67M	-89.58M
	EBITDA
-521.40M	-448.08M	-464.88M	-214.29M	-98.28M	-87.81M
	Net Income Common Stockholders
-509.63M	-463.93M	-402.27M	-239.64M	-100.08M	-87.82M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.67B	1.75B	1.08B	931.38M	245.97M	386.20M
	Total Assets
3.38B	3.51B	1.41B	1.01B	324.34M	392.83M
	Total Debt
87.21M	71.11M	29.22M	17.94M	16.78M	0.00
	Net Debt
-259.64M	-316.77M	-368.23M	-816.72M	-52.20M	-386.20M
	Total Liabilities
178.08M	205.50M	167.45M	52.56M	40.32M	46.98M
	Stockholders Equity
3.20B	3.31B	1.24B	953.61M	284.02M	345.84M
Cash Flow		Free Cash Flow
-600.01M	-475.05M	-364.67M	-176.44M	-127.95M	-47.78M
	Operating Cash Flow
-459.78M	-452.63M	-296.79M	-170.60M	-121.39M	-46.63M
	Investing Cash Flow
-1.43B	-2.01B	-773.31M	74.58M	-212.31M	-1.10M
	Financing Cash Flow
1.63B	2.45B	639.81M	861.55M	17.80M	374.87M

Vaxcyte Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 32.87
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCVX, the sentiment is Negative. The current price of 32.87 is below the 20-day moving average (MA) of 34.16, above the 50-day MA of 32.87, and below the 200-day MA of 76.32, indicating a neutral trend. The MACD of -0.22 indicates Positive momentum. The RSI at 43.55 is Neutral, neither overbought nor oversold. The STOCH value of 9.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PCVX.

Vaxcyte Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADMA	77 Outperform	$4.24B	21.02	78.45%	―	62.22%	―
VRNA	68 Neutral	$8.03B	―	-72.73%	―	―	-157.53%
Sector *	64 Neutral	¥344.44B	10.52	-2.88%	2.62%	11.64%	-5.91%
IONS	58 Neutral	$5.95B	―	-118.53%	―	-7.65%	-11.81%
ZLAB	56 Neutral	$3.91B	―	-32.05%	―	43.72%	28.63%
PCVX	50 Neutral	$4.24B	―	-19.66%	―	―	7.75%
CYTK	42 Neutral	$3.87B	―	435.49%	―	412.21%	1.75%

Vaxcyte Corporate Events

Vaxcyte Appoints Dr. Olivier Brandicourt to Board

On May 1, 2025, Vaxcyte, Inc. appointed Dr. Olivier Brandicourt to its Board of Directors as a Class III director, effective immediately, with his term ending at the 2026 annual stockholders meeting. Dr. Brandicourt is recognized as an independent director under Nasdaq rules, with no existing arrangements or transactions with the company that require disclosure. As part of his appointment, Dr. Brandicourt will receive an initial equity award valued at $800,000, vesting over 36 months, and an annual equity award valued at $450,000, alongside a $50,000 annual cash retainer, all subject to his continuous service.

Spark’s Take on PCVX Stock

According to Spark, TipRanks’ AI Analyst, PCVX is a Neutral.

Vaxcyte’s stock score reflects its position as a development-stage biotech firm with no revenue, high R&D expenses, and reliance on financing. The technical analysis indicates a bearish trend, while valuation metrics show challenges due to negative earnings. However, the company’s robust pipeline and recent positive clinical results provide optimism for the future. The earnings call and corporate events signal potential for growth, but regulatory and financial challenges remain.

To see Spark’s full report on PCVX stock, click here.

Vaxcyte Announces Positive Phase 2 Results for VAX-24

On March 31, 2025, Vaxcyte announced positive results from its Phase 2 study of VAX-24, a 24-valent pneumococcal conjugate vaccine candidate for infants, showing it was well-tolerated and elicited strong immune responses. The company plans to advance the VAX-24 Mid dose to a potential Phase 3 program, pending further study results, and has also announced the development of VAX-XL, a third-generation PCV candidate. These developments reinforce Vaxcyte’s commitment to expanding vaccine coverage and addressing the global burden of pneumococcal disease, with significant implications for future clinical programs and market positioning.